ORBIMED ADVISORS LLC

Q1 2020 13F-HR Detailed Holdings

Location
New York, NY
Holdings as of
3/31/2020
Date filed
5/15/2020
Form type
13F-HR
Num holdings
142
Total value ($000)
$5,950,362
Net value change ($000)
-1,053,974 (-15.0%)
New positions
32
Sold out positions
26
Turnover %
28.8%
Sector allocation + QoQ delta (equities-only)

Holdings broken out by other managers reported in the original SEC filing. View aggregated holdings

You are on the SEC detailed breakdown page. Rows are shown as reported in the filing (including other manager, discretion, and voting authority fields), and are not merged like the standard holdings view. Switch to aggregated holdings.

Snapshot: Change Analysis

Compared to Q4 2019
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
ARQT 139,281 NEW
BIIB 132,850 694.1%
PASG 109,666 NEW
PFE 98,315 NEW
GILD 88,789 419.0%
CNC 79,354 NEW
SYK 61,784 NEW
AGIO 58,638 NEW
IMARA INC 43,600 NEW
BMRN 42,738 1456.6%
Top Reduces (Value $000, Stocks/ETFs)
Synthorx, Inc. -371,560 -100.0%
Tricida, Inc. -151,329 -41.7%
ARQULE INC -99,800 -100.0%
DHR -98,058 -100.0%
ASND -94,898 -20.4%
SpringWorks Therapeutics, Inc. -85,099 -29.9%
INSP -79,044 -79.1%
REGN -70,189 -89.3%
EW -68,110 -67.1%
TNDM -68,038 -100.0%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 42,494 (0.7% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type Discretion Other Manager Sole Shared None

Other Managers

Num Name File Number
1 ORBIMED CAPITAL LLC 028-10410